Mauricio Catalá

958 total citations
16 papers, 622 citations indexed

About

Mauricio Catalá is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Mauricio Catalá has authored 16 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Mauricio Catalá's work include Glycosylation and Glycoproteins Research (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Mauricio Catalá is often cited by papers focused on Glycosylation and Glycoproteins Research (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Mauricio Catalá collaborates with scholars based in Cuba, Spain and United States. Mauricio Catalá's co-authors include Tania Crombet, Rolando Pérez, Patricia Marinello, Gabriela Gonzalez, Agustín Lage, Elia Neninger, Olga Torres, A. Lage, Gerardo Guillén and Juan C. Hernández and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

Mauricio Catalá

15 papers receiving 598 citations

Peers

Mauricio Catalá

ONCOL

IMMUN

PRM

RNMI

I. Leonard Cuba

Greta Garrido Cuba

Ailem Rabasa Cuba

Giselle Saurez Cuba

Patrick F. Joyce United States

Marta Osorio Cuba

Anuradha Bulusu United States

Olga Torres Cuba

Salim Yazji United States

Sajeve Thomas United States

I. Leonard Cuba

Mauricio Catalá

354 ×1.0

ONCOL

135 ×0.6

IMMUN

156 ×0.7

185 ×1.2

PRM

114 ×0.7

RNMI

Citations per year, relative to Mauricio Catalá Mauricio Catalá (= 1×) peers I. Leonard

Countries citing papers authored by Mauricio Catalá

Since Specialization

Citations

This map shows the geographic impact of Mauricio Catalá's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauricio Catalá with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauricio Catalá more than expected).

Fields of papers citing papers by Mauricio Catalá

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauricio Catalá. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauricio Catalá. The network helps show where Mauricio Catalá may publish in the future.

Co-authorship network of co-authors of Mauricio Catalá

This figure shows the co-authorship network connecting the top 25 collaborators of Mauricio Catalá. A scholar is included among the top collaborators of Mauricio Catalá based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauricio Catalá. Mauricio Catalá is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Catalá, Mauricio, Patricia Lorenzo-Luaces, Raúl Ramos, et al.. (2022). Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Oncology. 12. 823287–823287. 5 indexed citations

Lorenzo-Luaces, Patricia, Elia Neninger, Mauricio Catalá, et al.. (2021). Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer Immunology Immunotherapy. 70(6). 1735–1743. 8 indexed citations

Alert, José, et al.. (2013). Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer. 13(1). 299–299. 57 indexed citations

Alert, José, et al.. (2012). Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients.. Journal of Clinical Oncology. 30(15_suppl). 2515–2515. 2 indexed citations

Catalá, Mauricio, et al.. (2009). Seguridad de inmunoterapia con veneno de himenópteros en pauta agrupada: Perspectiva de enfermería. Anales del Sistema Sanitario de Navarra. 32(3). 2 indexed citations

Crombet, Tania, Mauricio Catalá, Mayra Ramos, et al.. (2006). Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biology & Therapy. 5(4). 375–379. 124 indexed citations

Neninger, Elia, Tania Crombet, Marta Osorio, et al.. (2005). Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial. Journal of Clinical Oncology. 23(16_suppl). 7210–7210. 3 indexed citations

Crombet, Tania, Mauricio Catalá, Sara González, et al.. (2005). Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy. Journal of Clinical Oncology. 23(16_suppl). 2554–2554. 5 indexed citations

Crombet, Tania, et al.. (2004). 282 Use of the humanized anti-EGFR antibody h-R3 and radiotherapy for the treatment of patients with high-grade astrocytic tumors. European Journal of Cancer Supplements. 2(8). 86–87. 1 indexed citations

10.

Crombet, Tania, Elia Neninger, Marta Osorio, et al.. (2004). Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial. Journal of Clinical Oncology. 22(14_suppl). 2514–2514. 1 indexed citations

11.

Crombet, Tania, Leonel Torres, Elia Neninger, et al.. (2003). Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer. Journal of Immunotherapy. 26(2). 139–148. 94 indexed citations

12.

Alfonso, Mauro, Ruby Alonso, Giselle Saurez, et al.. (2003). Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clinical Immunology. 107(2). 80–89. 77 indexed citations

13.

Gonzalez, Gabriela, Tania Crombet, Mauricio Catalá, et al.. (2003). Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Annals of Oncology. 14(3). 461–466. 91 indexed citations

14.

Crombet, Tania, Olga Torres, Elia Neninger, et al.. (2001). Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody against Epidermal Growth Factor Receptor. Cancer Biotherapy and Radiopharmaceuticals. 16(1). 93–102. 21 indexed citations

15.

Gonzalez, Gabriela, Tania Crombet, Mauricio Catalá, et al.. (1998). A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Annals of Oncology. 9(4). 431–435. 127 indexed citations

16.

Moreaux, J, et al.. (1984). [Results of the surgical treatment of pancreatic cancer. Study of a series of 96 surgically treated patients].. PubMed. 8(1). 11–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact